Journal of medicinal and pharmaceutical chemistry 2014-03-27

Cathepsin C inhibitors: property optimization and identification of a clinical candidate.

Mark Furber, Anna-Karin Tiden, Philip Gardiner, Antonio Mete, Rhonan Ford, Ian Millichip, Linda Stein, Andrew Mather, Elizabeth Kinchin, Christopher Luckhurst, Simon Barber, Peter Cage, Hitesh Sanganee, Rupert Austin, Kamaldeep Chohan, Raj Beri, Bob Thong, Alan Wallace, Victor Oreffo, Ray Hutchinson, Steve Harper, Judit Debreczeni, Jason Breed, Lisa Wissler, Karl Edman

Index: J. Med. Chem. 57(6) , 2357-67, (2014)

Full Text: HTML

Abstract

A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.


Related Compounds

Related Articles:

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

2013-10-01

[Genes Dev. 27(19) , 2086-98, (2013)]

Cathepsin C and plasma glutamate carboxypeptidase secreted from Fischer rat thyroid cells liberate thyroxin from the N-terminus of thyroglobulin.

2012-03-01

[Biochimie 94(3) , 719-26, (2012)]

The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C.

2012-10-01

[J. Immunol. 189(7) , 3734-40, (2012)]

Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants.

2013-03-15

[J. Biol. Chem. 288(11) , 7481-91, (2013)]

Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin.

2011-09-22

[Blood 118(12) , 3384-91, (2011)]

More Articles...